Gastroenterology Department of Centro Hospitalar Universitário de Lisboa Central, EPE, Lisbon, Portugal.
NOVA Medical School, Lisbon, Portugal.
J Gastrointest Cancer. 2024 Mar;55(1):435-443. doi: 10.1007/s12029-023-00989-2. Epub 2023 Nov 21.
Recent studies suggested a protective role of metformin in the development of colorectal cancer (CRC) and its precursors. We aimed to investigate if metformin was associated with a lower prevalence and number of colorectal polyps in diabetic patients and also adenomas, high-risk adenomas, and CRC.
Retrospective study on adult patients with diabetes mellitus followed in our hospital with a total colonoscopy between 2015 and 2019, treated with either metformin for > 5 years or other antidiabetic agent (control group). We assessed the number, size, and histopathology examination of proliferative lesions detected on colonoscopy.
We included 401 patients aged 69 ± 9 years, 57% males, divided into two groups: treated with metformin (n = 260) and without (n = 141). The number of polyps detected was significantly lower in patients under metformin (p = 0.014). There was a nonsignificant trend towards lower polyp detection rates in the metformin compared to the control group both in unadjusted analysis (50% vs 60%, p = 0.058) and multivariable adjusted analysis (odds ratio [OR] 0.68, 95% confidence interval [CI] 0.43-1.09, p = 0.111). In the latter, we identified male gender (OR 2.24, 95%CI 1.44-3.49, p < 0.001), age (OR 1.35 for every 10 years, 95%CI 1.07-1.71, p = 0.012), glycated hemoglobin value (OR 1.20 for every 1% increase, 95%CI 1.06-1.37, p = 0.005), and hypertension (OR 1.76, 95%CI 1.01-3.08, p = 0.046) as factors associated with a higher prevalence of polyps. We saw no statistically significant differences regarding adenoma (p = 0.231), high-risk adenoma (p = 0.810), and CRC (p = 0.705) diagnoses between groups.
In our study, metformin was associated with less colorectal polyps in diabetic patients compared to other treatment modalities. We observed a nonsignificant trend towards lower polyp detection rates in the metformin group both in unadjusted and adjusted analyses.
最近的研究表明,二甲双胍在结直肠癌(CRC)及其前体的发生发展中具有保护作用。我们旨在研究二甲双胍是否与糖尿病患者中结直肠息肉的发生率和数量较低相关,以及腺瘤、高危腺瘤和 CRC。
对 2015 年至 2019 年间在我院接受全结肠镜检查的使用二甲双胍治疗超过 5 年或使用其他降糖药物(对照组)的成年糖尿病患者进行回顾性研究。我们评估了结肠镜检查中发现的增生性病变的数量、大小和组织病理学检查结果。
我们纳入了 401 名年龄 69±9 岁、57%为男性的患者,分为两组:接受二甲双胍治疗(n=260)和未接受治疗(n=141)。接受二甲双胍治疗的患者中检测到的息肉数量明显较少(p=0.014)。未校正分析中,与对照组相比,二甲双胍组的息肉检出率呈下降趋势,但无统计学意义(50% vs 60%,p=0.058);多变量校正分析中,比值比(OR)为 0.68(95%置信区间 [CI] 0.43-1.09,p=0.111)。在后者中,我们发现男性(OR 2.24,95%CI 1.44-3.49,p<0.001)、年龄(每增加 10 岁,OR 1.35,95%CI 1.07-1.71,p=0.012)、糖化血红蛋白值(每增加 1%,OR 1.20,95%CI 1.06-1.37,p=0.005)和高血压(OR 1.76,95%CI 1.01-3.08,p=0.046)是与息肉发生率较高相关的因素。我们发现两组之间在腺瘤(p=0.231)、高危腺瘤(p=0.810)和 CRC(p=0.705)的诊断方面无统计学显著差异。
与其他治疗方法相比,我们的研究表明,二甲双胍可使糖尿病患者的结直肠息肉数量减少。在未校正和校正分析中,我们均观察到二甲双胍组的息肉检出率呈下降趋势,但无统计学意义。